need help? call toll free 877-866-7400 chat now chat now

toll free phone 877-866-7400

REDUCED PRICE!! FDA approved COVID-19 Rapid Tests In Stock! Order Now >>

We Carry Limited COVID-19 Supplies - Available Today HERE

Access Bio RCHM-02071 CareStart COVID-19 Antigen Rapid Test, 20/kit

By Access Bio | Mfr#: RCHM-02071 | Tiger#: TM108690
CareStart COVID-19 Antigen Rapid Test, 20 /kit ACBRCHM-02071


  • Rapid detection of SARS-CoV-2
  • Fast results in 10 minutes
  • Identifies with 88.4% sensitivity and 100% specificity
  • Authorized by the FDA under EUA [Emergency Use Authorization]
  • CLIA waived
List Price: $550.00
You Save: $319.19 - 58%


  • Volume Discounts

Availability:In Stock
Ships Out Within: 24 - 48 Hours
This product is only allowed to a Medical Professional

Overview for Access Bio RCHM-02071 CareStart COVID-19 Antigen Rapid Test, 20/kit

The CareStart COVID-19 Antigen Covid-19 Test is a lateral flow immunochromatographic assay for the detection of extracted nucleocapsid protein antigens specific to SARS-CoV-2 in swab specimens directly collected from symptomatic individuals who are suspected of COVID-19 by their healthcare providers.

Due to the highly contagious nature and global health crisis, SARS-CoV-2 has been designated as a pandemic by the World Health Organization (WHO) and continues to have devastating impacts on healthcare systems and the world economy including the U.S. To effectively end the SARS-CoV-2 pandemic, systematic screening and detection of both clinical and asymptomatic COVID-19 cases is critical.

As an intended point-of-care (POC) designated test with a 10 minute processing time, CareStart™ COVID-19 Antigen Test allows effective screening of COVID-19 infection on a large scale.

  • Lateral flow assay
  • Rapid results in 10 minutes
  • Nasopharyngeal swab specimen collection
  • Intended at POC setting (i.e., in patient care settings) by medical professionals operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation
  • Detect SARS-CoV-2 nucleocapsid protein antigen
  • Identify acute infection in symptomatic patients with 88.4% sensitivity and 100% specificity
  • Designated as a CLIA waived tests